Post by stcks on Mar 23, 2016 22:42:59 GMT
I have been thinking this since the first of the year "buy when there is blood in the streets". But I would not buy Valeant Pharmaceuticals (VRX).
Jim Cramer on Biotech and Presidential Politics
JIM CRAMER
Follow
Mar 23, 2016 12:34 PM EDT
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said the negative rhetoric about the biotech space will subside as Democratic presidential hopeful Bernie Sanders loses momentum. 'The drug companies have a window to go higher, including biotech,' Cramer said, adding that the rise of Valeant Pharmaceuticals (VRX) is moving up the entire group. For more biotech analysis, Cramer points to TheStreet's Biotech Bible.
Jim Cramer on Biotech and Presidential Politics
JIM CRAMER
Follow
Mar 23, 2016 12:34 PM EDT
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said the negative rhetoric about the biotech space will subside as Democratic presidential hopeful Bernie Sanders loses momentum. 'The drug companies have a window to go higher, including biotech,' Cramer said, adding that the rise of Valeant Pharmaceuticals (VRX) is moving up the entire group. For more biotech analysis, Cramer points to TheStreet's Biotech Bible.
